{"brief_title": "A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer", "brief_summary": "This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery for colon cancer and no previous chemotherapy. Patients will be randomized to receive either 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment is until disease progression and the target sample size is 500+ individuals.", "condition": "Colorectal Cancer", "intervention_type": "Drug", "intervention_name": "5 FU", "description": "As prescribed, in 2 week cycles", "arm_group_label": "2", "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - colon cancer; - complete tumor resection. Exclusion Criteria: - prior treatment with cytotoxic chemotherapy, radiotherapy, or immunotherapy for the currently treated colon cancer.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00069121.xml"}